- Christian Itin
- Founder & CSO
- Dr Martin Pule
- % Shareholding
- Late clinical
- Number of employees
- NASDAQ (June 2018)
- Clinical trials
Unless stated all financials at 30 June 2023.
Autolus is a clinical-stage biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T effector cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.
Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.
A leader in T-cell programming and manufacturing technology, Autolus works in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which they believe will offer cancer patients substantial benefits over the existing standard of care.
Syncona believes obe-cel has a differentiated safety profile and improved persistence to address limitations of current T cell therapies
- AUTO4 targeting T-cell lymphoma, a setting where there are currently no approved T cell therapies and substantial unmet clinical needs
Unmet medical need:
- In lead programme of obe-cel, only 30-40% of patients with aALL achieve long term remission with combination chemotherapy, the current standard of care*
- 8,400 patients p.a. in lead programme of aALL (estimated new patients globally diagnosed per annum)
- Estimated 3,000 relapsed / refractory ALL patients in EU / US
*Autolus corporate presentation
The Autolus pipeline
obe-cel - adult ALL
obe-cel - B-NHL
AUTO 1/22 - paediatric ALL
AUTO4 - TCL
obe-cel - PCNSL